<DOC>
	<DOCNO>NCT00406601</DOCNO>
	<brief_summary>The aim study ( * ) evaluate progression free survival rate 6 month , response rate , overall disease control rate , overall survival BAY-43-9006 soft tissue sarcoma patient . ( * ) per Protocol Amendment No . 1 16 April 2007 approve local IEC 24 July 2007</brief_summary>
	<brief_title>BAY-43-9006 Advanced , Metastatic Soft Tissue Sarcomas</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically document , progressive , advanced metastatic sarcoma adjuvant and/or first line anthracyclinebased regimen ; age &gt; =18 yr ; ECOG PS =2 ; least 1 measurable target lesion ; life expectancy &gt; =12 wks ; adequate medullary liver renal function ; write informed consent . metastatic brain disease ; pregnant breastfeeding patient ; serious infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>